Tag: Drug Manufacturing ⋅ Page 1

Professor Lietzan speaks to Akron law students about perils of patent reform

At a recent event at the University of Akron School of Law, Professor Erika Lietzan spoke about what she called the “assault on drug patents,” including patent reform activity in Congress as well as proposals to prevent drug companies from patenting any changes or improvements to their drugs after approval (so called “one and done” proposals).  She explained that medical…

Professor Lietzan’s Research Analyzes Patent Terms for New Medicine

A recent article in Bloomberg Law, U.S. Patent System Crimps Drug Innovation for Toughest Diseases, looks at the research of Professor Erika Lietzan and Kristina M.L. Acri about how the development of new drugs is affected by the U.S. patent system. Their research will be published in a forthcoming article. Their empirical research looked at 642 approved drugs to determine…

Professor Lietzan Quoted by CBS News on Pharmaceutical Manufacturing Recall

Professor Erika Lietzan was recently quoted by CBS News in a Moneywatch article relating to pharmaceutical manufacturing, “Drugmaker behind ibuprofen recall has history of FDA violations.” Last month New Jersey drugmaker Tris Pharma doubled its recall of infant ibuprofen, and CBS News spoke with Professor Lietzan about the company’s manufacturing history.  She described some of the “red flags” in a…